Overcoming resistance to STING agonist therapy to incite durable protective antitumor immunity.

ABSTRACT:

Background

Activating the Stimulator of Interferon Genes (STING) adaptor incites antitumor immunity against immunogenic tumors in mice, prompting clinical trials to test STING activators. However, STING signaling in the tumor microenvironment (TME) during development of Lewis lung carcinoma (LLC) suppresses antitumor immunity to promote tumor growth. We hypothesized that local immune balance favoring suppression of antitumor immunity also attenuates antitumor responses following STING activation. The purpose of this study was to evaluate how STING activation impacts antitumor responses in mice bearing LLC tumors.

Methods

Mice bearing established LLC tumors were treated with synthetic cyclic diadenyl monophosphate (CDA) to activate STING. Mice were monitored to assess LLC tum

SUBMITTER: Lemos H 

PROVIDER: S-EPMC7451475 | biostudies-literature | 2020 Aug

REPOSITORIES: biostudies-literature